A meta-analysis published in the Journal of the American Geriatrics Society found that SGLT2 inhibitors such as empagliflozin and dapagliflozin reduced heart failure hospitalizations and cardiovascular deaths among people ages 65 and older with cardiovascular disease. The analysis of data from 24,889 patients found that the drugs also reduced all-cause mortality, although risk of genital infections increased.
Patients with diabetes: Subgroup analyses, including for patients with type 2 diabetes, also showed significant reductions in risk.
Full Story: Medscape (10/14)